PP
INMB icon

Praetorian PR’s INmune Bio INMB Stock Holding History

Praetorian PR’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,904
Closed -$49.3K – 17
2025
Q2 		$49.3K Buy
5,904
+2,000
+51% +$14.7K 0.05% 10
2025
Q1 		$1.03M Buy
3,904
+3,112
+393% +$24.7K 0.45% 20
2024
Q4 		$133K Buy
+792
New +$4.13K 0.05% 22

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Praetorian PR's INMB Position: Q2 2025 in Review

Praetorian PR sold out of INmune Bio (INMB) in Q2 2025, closing a stake of 865,000 shares — an estimated $6.35M sold.

Praetorian PR first reported a position in INMB in Q2 2024 and held it in 4 quarters. The position peaked at $6.76M in Q1 2025. 79 funds tracked by Wall St. Rank hold INMB as of Q2 2025.

  • Praetorian PR reported no remaining INmune Bio position as of Q2 2025 after selling out during the quarter.
  • Praetorian PR sold 865,000 INmune Bio shares in Q2 2025, an estimated $6.35M.
  • Praetorian PR first reported a position in INmune Bio in Q2 2024 and held it in 4 quarters.
  • Praetorian PR's INmune Bio position peaked at $6.76M in Q1 2025.
  • 79 funds tracked by Wall St. Rank held INmune Bio as of Q2 2025.

Based on Praetorian PR's 13F filing for Q2 2025, filed 14 Aug 2025.